CONTINUUSly Transforming Pharma Manufacturing

Small reaction volumes allow for greater control. At the same time, plant-wide QbD and real-time closed-loop control ensure every critical parameter remains in spec, delivering lot-to-lot consistency that batch processes can’t match.

Lower COGS, domestic production, and rapid production timelines increase access for patients worldwide.

Reactive, highly potent, or toxic intermediates are consumed instantly; there is no accumulation, and therefore, no risk. Significantly smaller process volumes and minimal material handling also improve operator safety.

1. Fewer and smaller skids, higher yields, and minimal labor and testing. Efficiency is engineered in, not bolted on, resulting in a ~30–50% reduction in COGS.

Continuous manufacturing eliminates idle “white space,” compressing lead times from quarters to weekends. This feature also greatly reduces COGS.

Up to 90% less floor space, work-in-process inventory is eliminated, and fewer personnel are required.

Higher yields and solvent-saving recovery loops slash emissions and waste. Decreased wash solvent requirements also contribute to this benefit.

High-surface-area small flow reactors enable reactions that are not practical and sometimes not safe in large, traditional vessels.

When more clinical trial or commercial product is needed, run the line longer; capacity grows with time, not tank size.